<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045144</url>
  </required_header>
  <id_info>
    <org_study_id>214709</org_study_id>
    <secondary_id>2021-000357-26</secondary_id>
    <nct_id>NCT05045144</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.</brief_title>
  <official_title>A Phase III, Observer-blind, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical lot-to-lot consistency of the&#xD;
      respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy&#xD;
      non-pregnant women 18-49 years of age (YOA). In addition, this study will evaluate&#xD;
      immunogenicity, safety and reactogenicity from co-administration of RSV MAT vaccine and GSK's&#xD;
      quadrivalent seasonal influenza (Flu D-QIV) vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer-blind study. Participants and study evaluators will be unaware of vaccine administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting solicited administration site events in all study groups</measure>
    <time_frame>From Day 1 to Day 7 included</time_frame>
    <description>Assessed solicited administration site events include pain, redness and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting solicited systemic events in all study groups</measure>
    <time_frame>From Day 1 to Day 7 included</time_frame>
    <description>Assessed solicited systemic events include fever, headache, gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea, abdominal pain) and fatigue. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (≥) 38.0 °C/ 100.4°F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting unsolicited adverse events (AEs) in all study groups</measure>
    <time_frame>From Day 1 to Day 30 included</time_frame>
    <description>Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting serious adverse events (SAEs) in all study groups</measure>
    <time_frame>From Day 1 to Day 30 included</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RSV MAT immunoglobulin G (IgG) concentrations for participants in RSV1, RSV2 and RSV3 groups at Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>Serological assays for the determination of IgG antibodies against RSV MAT are performed by Enzyme-Linked Immunosorbent Assay (ELISA). RSV MAT IgG concentrations are expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (ELU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flu D-QIV haemagglutinin inhibition (HI) antibody titers against 4 influenza strains for participants in Flu+P group and RSV+Flu pooled group at Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>Flu D-QIV HI antibody titers against 4 influenza strains (A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage) are expressed as geometric mean titers (GMTs), as assessed by HI assay. RSV+Flu pooled group consists of participants pooled from RSV1+Flu, RSV2+Flu and RSV3+Flu groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting SAEs from first vaccination up to study end in all study groups</measure>
    <time_frame>From first vaccination up to study end (Day 1 to Day 181)</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV A neutralizing antibody titers for participants in RSV+Flu pooled group and RSV pooled group at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of antibodies against RSV A are performed by neutralization assay. RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs). The RSV+Flu pooled group consists of participants pooled from RSV1+Flu, RSV2+Flu and RSV3+Flu groups. The RSV pooled group consists of participants pooled from RSV1, RSV2 and RSV3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate (SCR) to Flu D-QIV HI antibody titers against 4 influenza strains for participants in Flu+P group and RSV+Flu pooled group at Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>The SCR is defined as the proportion of participants with: A Day 1 (pre-vaccination) serum anti-HI titer &lt;1:10 and a Day 31 (post-vaccination) serum anti-HI titer ≥1:40, or. A Day 1 (pre-vaccination) serum anti-HI titer ≥ 1:10 and a fold increase (post/pre) ≥ 4 at Day 31. The 4 influenza strains assessed are: A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage. The RSV+Flu pooled group consists of participants pooled from RSV1+Flu, RSV2+Flu and RSV3+Flu groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV B neutralizing antibody titers for participants in RSV+Flu pooled group and RSV pooled group at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of antibodies against RSV B are performed by neutralization assay. RSV B neutralizing antibody titers are expressed as GMTs. The RSV+Flu pooled Group consists of participants pooled from RSV1+Flu, RSV2+Flu and RSV3+Flu groups. The RSV pooled Group consists of participants pooled from RSV1, RSV2 and RSV3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV MAT IgG concentrations for participants in RSV+Flu pooled group and RSV pooled group at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of IgG antibodies against RSV MAT are performed by ELISA. RSV MAT IgG concentrations are expressed as GMCs, in ELU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flu D-QIV HI antibody titers against 4 influenza strains for participants in Flu+P group and RSV+Flu pooled group at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Flu D-QIV HI antibody titers against 4 influenza strains (A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage) are expressed as geometric mean titers (GMTs), as assessed by HI assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate (SPR) to Flu D-QIV HI antibody titers for participants in Flu+P group and RSV+Flu pooled group at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>SPR is measured by the proportion of participants achieving an HI antibody titer ≥1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV A neutralizing antibody titers for participants in RSV1, RSV2 and RSV 3 groups at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. RSV A neutralizing antibody titers are expressed as GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV B neutralizing antibody titers for participants in RSV1, RSV2 and RSV 3 groups at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of antibodies against RSV B are performed by neutralization assay. RSV B neutralizing antibody titers are expressed as GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV MAT IgG concentrations for participants in RSV1, RSV2 and RSV3 groups at Day 1 and Day 31</measure>
    <time_frame>At Day 1 and Day 31</time_frame>
    <description>Serological assays for the determination of IgG antibodies against RSV MAT are performed by ELISA. RSV MAT IgG concentrations are expressed as GMCs, in ELU/mL.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">1541</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>RSV1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV1 Group receive one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV2 Group receive one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV3 Group receive one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV1+Flu Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV1+Flu Group receive one dose of RSV MAT Lot 1 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV2+Flu Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV2+Flu Group receive one dose of RSV MAT Lot 2 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV3+Flu Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the RSV3+Flu Group receive one dose of RSV MAT Lot 3 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flu+P Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the Flu+P Group receive one dose of Flu D-QIV vaccine co-administered with one dose of Placebo, intramuscularly, at Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV MAT Lot 1 vaccine (GSK3888550A)</intervention_name>
    <description>One dose of RSV MAT Lot 1 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.</description>
    <arm_group_label>RSV1 Group</arm_group_label>
    <arm_group_label>RSV1+Flu Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV MAT Lot 2 vaccine (GSK3888550A)</intervention_name>
    <description>One dose of RSV MAT Lot 2 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.</description>
    <arm_group_label>RSV2 Group</arm_group_label>
    <arm_group_label>RSV2+Flu Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV MAT Lot 3 vaccine (GSK3888550A)</intervention_name>
    <description>One dose of RSV MAT Lot 3 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.</description>
    <arm_group_label>RSV3 Group</arm_group_label>
    <arm_group_label>RSV3+Flu Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flu D-QIV vaccine</intervention_name>
    <description>One dose of Flu D-QIV vaccine administered intramuscularly: - in the deltoid region of the right arm, at Day 1 for the RSV1+Flu, RSV2+Flu and RSV3+Flu groups. - in the deltoid region of the left arm, at Day 1 for the Flu+P group. - in the deltoid region of the non-dominant arm, at Day 31 for the RSV1, RSV2 and RSV3 groups, as an optional vaccination for participants to provide standard of care.</description>
    <arm_group_label>Flu+P Group</arm_group_label>
    <arm_group_label>RSV1+Flu Group</arm_group_label>
    <arm_group_label>RSV2+Flu Group</arm_group_label>
    <arm_group_label>RSV3+Flu Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.</description>
    <arm_group_label>Flu+P Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who, in the opinion of the investigator, can and will comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
          -  Written or witnessed/thumb printed informed consent obtained from the participant&#xD;
             prior to performance of any study specific procedure.&#xD;
&#xD;
          -  Healthy female participants; as established by medical history and clinical&#xD;
             examination, aged 18 to 49 years at the time of the first study intervention&#xD;
             administration.&#xD;
&#xD;
               -  Female participants of childbearing potential may be enrolled in the study, if&#xD;
                  the participant:&#xD;
&#xD;
               -  has practiced adequate contraception for 1 month prior to study intervention&#xD;
                  administration, and&#xD;
&#xD;
               -  has a negative pregnancy test on the day of study intervention administration,&#xD;
                  and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period&#xD;
                  and for 1 month after completion of the study intervention administration.&#xD;
&#xD;
          -  No local condition precluding injection in both left and right deltoid muscles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical conditions&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the study interventions;&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination;&#xD;
&#xD;
          -  Current autoimmune disorder, for which the participant has received immune-modifying&#xD;
             therapy within 6 months, before study vaccination;&#xD;
&#xD;
          -  Hypersensitivity to latex;&#xD;
&#xD;
          -  Acute or chronic clinically significant abnormality or poorly controlled pre-existent&#xD;
             co-morbidities or any other clinical conditions, as determined by physical examination&#xD;
             or medical history that, in the opinion of the investigator, might pose additional&#xD;
             risk to the participant due to participation in the study;&#xD;
&#xD;
          -  Significant or uncontrolled psychiatric illness;&#xD;
&#xD;
          -  Recurrent history or uncontrolled neurological disorders or seizures;&#xD;
&#xD;
          -  Documented HIV-positive participant;&#xD;
&#xD;
          -  Body mass index &gt; 40 kg/m^2;&#xD;
&#xD;
          -  Any clinically significant* hematological parameter and/or biochemical laboratory&#xD;
             abnormality.&#xD;
&#xD;
             *The investigator should use his/her clinical judgment to decide which abnormalities&#xD;
             are clinically significant.&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the participant due to participation in the study.&#xD;
&#xD;
        Prior/Concomitant therapy&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study&#xD;
             intervention(s) during the period starting 30 days before study intervention (Day -29&#xD;
             to Day 1), or planned use during the study period;&#xD;
&#xD;
          -  Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period;&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products or plasma derivatives&#xD;
             during the period starting 3 months before the study intervention or planned&#xD;
             administration during the study period;&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs during&#xD;
             the period starting 3 months prior to the first study intervention dose(s). For&#xD;
             corticosteroids, this will mean prednisone 5 mg/day, or equivalent. Inhaled and&#xD;
             topical steroids are allowed;&#xD;
&#xD;
          -  Planned administration/administration of a vaccine not foreseen by the study protocol&#xD;
             within the period starting 30 days before and ending 30 days after the vaccination&#xD;
             dose;&#xD;
&#xD;
          -  Administration of a seasonal influenza vaccine during the 6 months preceding entry&#xD;
             into the study;&#xD;
&#xD;
          -  Previous experimental vaccination against RSV.&#xD;
&#xD;
        Prior/Concurrent clinical study experience Concurrently participating in another clinical&#xD;
        study, at any time during the study period, in which the participant has been or will be&#xD;
        exposed to an investigational or a non-investigational vaccine/product;&#xD;
&#xD;
        Other exclusions&#xD;
&#xD;
          -  Pregnant or lactating female;&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions;&#xD;
&#xD;
          -  Alcoholism or substance use disorder within the past 24 months based on the presence&#xD;
             of two or more of the following abuse criteria: hazardous use, social/interpersonal&#xD;
             problems related to use, neglected major roles to use, withdrawal tolerance, use of&#xD;
             larger amounts or longer, repeated attempts to quit or control use, much time spent&#xD;
             using, physical or psychological problems related to use, activities given up to use,&#xD;
             craving;&#xD;
&#xD;
          -  Any study personnel or their immediate dependents, family, or household members.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only healthy non-pregnant women 18-49 YOA are included in the study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mira Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Finley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel H Brune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leea Reed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robin Kroll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3S 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Derek W. Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Malcolm Hedgcock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Murdo Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Dzongowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Peterson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Noah Vale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Tellier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Naveen Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ginette Girard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Charles-Borromée</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Sebastien Paquette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Carbonneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benita Ukkonen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Susanna Koski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Susanna Koski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lauri Peltonen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pauliina Paavola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ilkka Seppa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Outi Laajalahti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marjaana Sipila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ilkka Seppa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dae Won Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hee Jin Cheong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcorcón/Madrid</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ángel Gil de Miguel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dolores Ochoa Mazarro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>María Ángeles Gálvez Múgica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pablo Rojo Conejo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto Borobia Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Belén Ruiz Antorán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Federico Martinón-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lina Perez Breva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus Maternal vaccine</keyword>
  <keyword>Flu Quadrivalent influenza vaccine</keyword>
  <keyword>Lot-to-lot consistency</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Reactogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

